Retroinverso analogs of spadin display increased antidepressant effects

Psychopharmacology

Volumn 232, Issue 3, 2015, Pages 561-574

  Veyssiere, Julie ^a,b   Moha Ou Maati, Hamid ^a,b,c   Mazella, Jean ^a,b   Gaudriault, Georges ^d   Moreno, Sébastien ^a,b   Heurteaux, Catherine ^a,b   Borsotto, Marc ^a,b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^d Medincell SA   (France)

Author keywords

Depression; Electrophysiology; Retro inverso; Spadin; TREK 1

Indexed keywords

ANTIDEPRESSANT AGENT; PEPTIDE; POTASSIUM CHANNEL PROTEIN TREK-1; SPADIN PEPTIDE; TANDEM PORE DOMAIN POTASSIUM CHANNEL;

ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DEPRESSION; DRUG DESIGN; DRUG EFFECTS; ELECTROPHYSIOLOGY; HEK293 CELL LINE; HUMAN; MALE; METABOLISM; MOUSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DRUG DESIGN; ELECTROPHYSIOLOGICAL PROCESSES; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; PEPTIDES; POTASSIUM CHANNELS, TANDEM PORE DOMAIN;

EID: 84939897138     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3683-2     Document Type: Article

References (34)

1. Aizawa Y, Ueda K, Scornik F, Cordeiro JM, Wu Y, Desai M, Guerchicoff A, Nagata Y, Iesaka Y, Kimura A, Hiraoka M, Antzelevitch C (2007) A novel mutation in KCNQ1 associated with a potent dominant negative effect as the basis for the LQT1 form of the long QT syndrome. J Cardiovasc Electrophysiol 18:972-977
2. Alloui A, Zimmermann K, Mamet J, Duprat F, Noel J, Chemin J, Guy N, Blondeau N, Voilley N, Rubat-Coudert C, Borsotto M, Romey G, Heurteaux C, Reeh P, Eschalier A, Lazdunski M (2006) TREK-1, a K+ channel involved in polymodal pain perception. EMBO J 25:2368-2376
3. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF (2001) Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50:77-82
4. Caldarone BJ, George TP, Zachariou V, Picciotto MR (2000) Gender differences in learned helplessness behavior are influenced by genetic background. Pharmacol Biochem Behav 66:811-817
5. Checler F, Mazella J, Kitabgi P, Vincent JP (1986) High-affinity receptor sites and rapid proteolytic inactivation of neurotensin in primary cultured neurons. J Neurochem 47:1742-1748
6. Chorev M, Goodman M (1995) Recent developments in retro peptides and proteins - an ongoing topochemical exploration. Trends Biotechnol 13:438-445
7. Dooley CT, Chung NN, Wilkes BC, Schiller PW, Bidlack JM, Pasternak GW, Houghten RA (1994) An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science 266:2019-2022
8. Downes MA, Whyte IM, Isbister GK (2005) QTc abnormalities in deliberate self-poisoning with moclobemide. Intern Med J 35:388-391
9. Ducroq J, Moha ou Maati H, Guilbot S, Dilly S, Laemmel E, Pons-Himbert C, Faivre JF, Bois P, Stucker O, Le Grand M (2010) Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). Br J Pharmacol 159:93-101
10. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ, Cantilena LR (2004) Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15:475-495
11. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK (2003) The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 64:1465-1475
12. Heist EK, Ruskin JN (2005) Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians. Heart Rhythm 2:S1-S8
13. Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M (2004) TREK-1, a K(+) channel involved in neuroprotection and general anesthesia. Embo J 23:2684-2695
14. Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M (2006a) Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 137:241-251
15. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng X, Noble F, Blondeau N, Widmann C, Gobbi G, Costentin J, Debonnel G, Lazdunski M (2006b) Deletion of TREK-1, a background potassium channel, results in a depression-resistant phenotype. Nat Neurosci 9:1134-1141
16. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M (2000) Polyunsaturated fatty acids are potent neuroprotectors. Embo J 19:1784-1793
17. Malberg JE, Schechter LE (2005) Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 11:145-155
18. Mazella J, Zsurger N, Navarro V, Chabry J, Kaghad M, Caput D, Ferrara P, Vita N, Gully D, Maffrand JP, Vincent JP (1998) The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. J Biol Chem 273:26273-26276
19. Mazella J, Petrault O, Lucas G, Deval E, Beraud-Dufour S, Gandin C, El-Yacoubi M, Widmann C, Guyon A, Chevet E, Taouji S, Conductier G, Corinus A, Coppola T, Gobbi G, Nahon JL, Heurteaux C, Borsotto M (2010) Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol 8:e1000355
20. Moha ou Maati H, Peyronnet R, Devader C, Veyssiere J, Labbal F, Gandin C, Mazella J, Heurteaux C, Borsotto M (2011a) A human TREK-1/HEK cell line: a highly efficient screening tool for drug development in neurological diseases. PLoS ONE 6:e25602
21. Moha ou Maati H, Veyssiere J, Labbal F, Coppola T, Gandin C, Widmann C, Mazella J, Heurteaux C, Borsotto M (2011b) Spadin as a new antidepressant: absence of TREK-1-related side effects. Neuropharmacology 62:278-288
22. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007) Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370:851-858
23. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, Gliemann J, Moestrup SK, Madsen P (1999) Propeptide cleavage conditions sortilin/neurotensin receptor-3 for ligand binding. Embo J 18:595-604
24. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25
25. Noel J, Zimmermann K, Busserolles J, Deval E, Alloui A, Diochot S, Guy N, Borsotto M, Reeh P, Eschalier A, Lazdunski M (2009) The mechano-activated K+ channels TRAAK and TREK-1 control both warm and cold perception. EMBO J 28:1308-1318
26. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732
27. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809
28. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, Rosenzweig-Lipson S (2005) Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2:590-611
29. Sicouri S, Antzelevitch C (2008) Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf 7:181-194
30. Taylor EM, Otero DA, Banks WA, O'Brien JS (2000) Retro-inverso prosaptide peptides retain bioactivity, are stable In vivo, and are blood-brain barrier permeable. J Pharmacol Exp Ther 295:190-194
31. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, Gobbi M, Mann DM, Allsop D (2010) Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 49:3261-3272
32. Tsirka SE, Gualandris A, Amaral DG, Strickland S (1995) Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377:340-344
33. Van Regenmortel MH, Muller S (1998) D-peptides as immunogens and diagnostic reagents. Curr Opin Biotechnol 9:377-382
34. Weeden T, Stefano J, Duan S, Edling A, Hou L, Chuang WL, Perricone MA, Pan C, Dzuris JL (2011) A retro-inverso alpha-melanocyte stimulating hormone analog with MC1R-binding selectivity. J Pept Sci 17:47-55